NCT03673943View on ClinicalTrials.gov

Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 23, 2018

Primary Completion Date

March 23, 2019

Study Completion Date

August 7, 2019

Conditions

Neuroendocrine Tumors

Interventions

DRUG

64Cu-DOTATATE

Detection of somatostatin positive lesions in NET

Trial Locations (1)

77042

Excel Diagnostics and Nuclear Oncology Center, Houston

All Listed Sponsors

lead

Radiomedix, Inc.

INDUSTRY

NCT03673943 - Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE | Biotech Hunter | Biotech Hunter